Charles River Laboratories Intl. Inc vs Global X Lithium & Battery Tech ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $302.65 (market cap $14.23B), while Global X Lithium & Battery Tech ETF trades at $69.77 (market cap $1.45B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 9.8× Global X Lithium & Battery Tech ETF's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Global X Lithium & Battery Tech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Global X Lithium & Battery Tech ETF for 56 Days on average.
| CRL | LIT | |
|---|---|---|
Market Cap | $14.23B | $1.45B |
Volume | 1,176,885 | 89,392 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $310.77 | $91.62 |
52-Week Low | $149.93 | $53.92 |
Typical Hold Time | 33 Days | 56 Days |
Enterprise Value | $17.06B | — |
Signals from Pluang's Aura AI — not financial advice
CRL trades at $304.01, up 1.24% on the day, near the consensus price target of $305.50. The stock shows a bullish technical trend with strong analyst support (73% buy ratings) and has beaten EPS estimates for three consecutive quarters. However, fundamentals reveal challenges with negative net income margins and a high P/E ratio of 684.85, while recent news highlights a strategic growth plan targeting 5-7% revenue growth and $300 million in savings by 2030.
The outlook is cautiously optimistic given strong analyst sentiment and recent earnings beats, but high valuation and profitability concerns pose risks. Investment opportunity hinges on successful execution of the new growth strategy to improve margins, while key risks include persistent negative earnings, competitive pressures, and execution missteps in achieving long-term targets.
LIT (Global X Lithium & Battery Tech ETF) trades at $69.51, down 2.2% with mixed technical signals showing a bullish overall trend but bearish moving averages and oscillators. Recent news highlights significant short interest decline (53.1% drop in September 2026) and positive catalysts from EV adoption trends. The ETF's performance reflects ongoing volatility in lithium markets amid shifting commodity prices and global electrification policies.
Outlook remains driven by long-term EV growth, though near-term risks include lithium price volatility and geopolitical tensions. Investment opportunity lies in exposure to battery technology leaders, balanced by sector-specific supply chain and regulatory uncertainties that could impact shareholder returns.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →LIT invests in the full lithium cycle, from mining and refining to battery production and EV manufacturing. It tracks the Solactive Global Lithium Index, with top holdings including Rio Tinto, Albemarle, and Tesla, as well as major battery makers like Samsung SDI.
Read more on LIT →